170 related articles for article (PubMed ID: 27091587)
1. Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency.
Scaramucci L; Niscola P; Palombi M; Tendas A; Giovannini M; Fabritiis Pd
Turk J Haematol; 2016 Mar; 33(1):77-8. PubMed ID: 27091587
[No Abstract] [Full Text] [Related]
2. [Eltrombopag increases thrombocyte count and reduces the bleeding risk].
Med Monatsschr Pharm; 2007 Oct; 30(10):390-1. PubMed ID: 17966290
[No Abstract] [Full Text] [Related]
3. Eltrombopag in chronic idiopathic thrombocytopenic purpura.
Panzer S; Pabinger I
Lancet; 2009 Feb; 373(9664):607-8. PubMed ID: 19231614
[No Abstract] [Full Text] [Related]
4. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag in thrombocytopenia.
Zimmer J; Hentges F; Andrès E
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
[No Abstract] [Full Text] [Related]
6. Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.
Cook L; Cooper N
Drug Des Devel Ther; 2010 Jul; 4():139-45. PubMed ID: 20689640
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.
Jolliffe E; Romeril K
Intern Med J; 2014 Jul; 44(7):697-9. PubMed ID: 25041772
[TBL] [Abstract][Full Text] [Related]
8. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
[TBL] [Abstract][Full Text] [Related]
9. What is publication? The case of eltrombopag.
Benham L; Guo L; Turner R
Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
[No Abstract] [Full Text] [Related]
10. Management of Primary Immune Thrombocytopenia With Eltrombopag in a Patient With Recent Acute Coronary Syndrome.
Bermejo N; Sigüenza R; Ibáñez F
Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):56-57. PubMed ID: 27650208
[No Abstract] [Full Text] [Related]
11. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
13. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
Haselboeck J; Kaider A; Pabinger I; Panzer S
Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag for chronic immune thrombocytopenia.
Milosevic I; Slade E; Drysdale H;
Lancet; 2016 Jan; 387(10016):336. PubMed ID: 26842445
[No Abstract] [Full Text] [Related]
15. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
Özdemirkıran F; Payzın B; Kiper HD; Kabukçu S; Akgün Çağlıyan G; Kahraman S; Sevindik ÖG; Ceylan C; Kadıköylü G; Şahin F; Keskin A; Arslan Ö; Özcan MA; Kabukçu G; Görgün G; Bolaman Z; Büyükkeçeci F; Bilgir O; Alacacıoğlu İ; Vural F; Tombuloğlu M; Gökgöz Z; Saydam G
Turk J Haematol; 2015 Dec; 32(4):323-8. PubMed ID: 25914025
[TBL] [Abstract][Full Text] [Related]
16. Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review.
Wang X; Liu X; Wang L; Wang JY; Li A
Blood Coagul Fibrinolysis; 2019 Mar; 30(2):71-74. PubMed ID: 30720490
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura.
Chiou TJ; Chang YF; Wang MC; Kao CW; Lin HY; Chen TY; Hsueh EJ; Lan YJ; Sung YC; Lin SF; Bai LY; Chen CG
Transl Res; 2015 Dec; 166(6):750-761.e4. PubMed ID: 26477577
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
Grainger JD;
Lancet; 2016 Jan; 387(10016):336-337. PubMed ID: 26842444
[No Abstract] [Full Text] [Related]
19. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.
Psaila B; Bussel JB; Linden MD; Babula B; Li Y; Barnard MR; Tate C; Mathur K; Frelinger AL; Michelson AD
Blood; 2012 Apr; 119(17):4066-72. PubMed ID: 22294727
[TBL] [Abstract][Full Text] [Related]
20. Emerging strategies to treat chronic immune thrombocytopenic purpura.
Newland A
Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]